Skip to main content
. Author manuscript; available in PMC: 2016 Mar 17.
Published in final edited form as: Immunity. 2015 Mar 10;42(3):538–551. doi: 10.1016/j.immuni.2015.02.007

Figure 3. Icos−/− ILC2s fail to induce AHR and lung inflammation.

Figure 3

A) ILC2s and splenic CD4+ T cells were purified from BALB/cBYJ and Icos−/− mice using FACS. WT ILC2s (1.5 × 104 cells/mouse) combined with splenic Icos−/− CD4+ T cells (3 × 106 cells/mouse) or Icos−/− ILC2s combined WT CD4+ T cells were injected into NSG mice intravenously followed by 3 intranasal challenges with rm-IL-33 or PBS on 3 consecutive days. One day after the last challenge lung function was measured and samples were collected. B) Lung resistance and C) dynamic compliance. D) Lung histology after PBS or IL-33 treatment. E) Total eosinophils in bronchoalveolar lavage in PBS or IL-33 treated mice, F) Total ILC2s in lungs after PBS or IL-33 treatment. Data are representative of 2 independent experiments and shown as mean ± SEM (n=3–5, *: P<0.05).